retatrutide effects clinical trial Side Research Perceived benefits of treatment for

People who found a single GLP-1 drug intolerable at its top dose sometimes find the two-pathway approach easier to live with, precisely because neither compound is being pushed to its limit

The titration regimen described in the NEJM 2023 obesity trial (Jastreboff et al.) progressed as follows: Weeks 14 : 2 mg once weekly Weeks 58 : 4 mg once weekly Weeks 912 : 8 mg once weekly Week 12 onwards : Up to 12 mg once weekly (in higher-dose cohorts) This regimen was used exclusively within a regulated clinical trial setting and does not constitute an approved dosing schedule

The mechanistic case for the stack is the same regardless of sex

The remaining authors declare no competing interests

Keep portions small and simple